STOCK TITAN

[Form 4] Encompass Health Corp Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Encompass Health (EHC) reported a director’s Form 4 activity on 10/15/2025. The director received 7 RSUs credited in connection with a common stock dividend and acquired 223 shares through the Directors Deferred Stock Investment Plan.

The RSUs were credited based on the company’s $0.19 per share dividend and a closing price of $123.65. The 223 shares were purchased at a weighted average price of $123.21. Following these transactions, the director beneficially owns 6,904 shares directly.

Encompass Health (EHC) ha riportato un'attività del modulo 4 del direttore il 15/10/2025. Il direttore ha ricevuto 7 RSU accreditate in relazione a un dividendo di azioni comuni e ha acquistato 223 azioni attraverso il Directors Deferred Stock Investment Plan.

Le RSU sono state accreditate sulla base del dividendo della società di $0.19 per azione e di una chiusura del prezzo di $123.65. Le 223 azioni sono state acquistate a un prezzo medio ponderato di $123.21. Dopo queste operazioni, il direttore detiene in modo beneficiario 6,904 azioni direttamente.

Encompass Health (EHC) informó una actividad del Formulario 4 del director el 15/10/2025. El/la director(a) recibió 7 RSU acreditadas en relación con un dividendo de acciones comunes y adquirió 223 acciones a través del Directors Deferred Stock Investment Plan.

Las RSU se acreditaron sobre la base del dividendo de la empresa de $0.19 por acción y un precio de cierre de $123.65. Las 223 acciones se compraron a un precio medio ponderado de $123.21. Después de estas transacciones, el/la director(a) posee de manera beneficiosa 6,904 acciones directamente.

Encompass Health (EHC)는 이사(감) 관할 Form 4 활동을 2025년 10월 15일에 보고했습니다. 이사는 일반 주식 배당과 관련하여 7 RSU를 수령했고 223주를 Directors Deferred Stock Investment Plan을 통해 취득했습니다.

RSU는 회사의 주당 배당금 $0.19와 마감가 $123.65를 기준으로 적립되었습니다. 223주는 가중 평균가 $123.21로 매수되었습니다. 이 거래 후 이사는 직접적으로 6,904주를 유익하게 소유합니다.

Encompass Health (EHC) a signalé une activité Form 4 du directeur le 15/10/2025. Le directeur a reçu 7 RSU créditées dans le cadre d’un dividende d’actions ordinaires et a acquis 223 actions via le Directors Deferred Stock Investment Plan.

Les RSU ont été créditées sur la base du dividende de $0.19 par action et d’un cours de clôture de $123.65. Les 223 actions ont été achetées à un prix moyen pondéré de $123.21. Suite à ces transactions, le directeur détient directement de façon bénéficiaire 6,904 actions.

Encompass Health (EHC) meldete eine Director’s Form 4-Aktivität am 10/15/2025. Der Direktor erhielt 7 RSUs, die im Zusammenhang mit einer Dividende auf Stammaktien gutgeschrieben wurden, und erwarb 223 Aktien durch den Directors Deferred Stock Investment Plan.

Die RSUs wurden basierend auf der Dividende des Unternehmens von $0.19 pro Aktie und einem Schlusskurs von $123.65 gutgeschrieben. Die 223 Aktien wurden zu einem gewichteten Durchschnittspreis von $123.21 gekauft. Nach diesen Transaktionen besitzt der Direktor direkt wirtschaftlich 6,904 Aktien.

Encompass Health (EHC) أبلغ عن نشاط نموذج المدير 4 في 15/10/2025. تلقى المدير 7 RSU معتمدة فيما يتعلق بتوزيع أسهم عادية واشتُري 223 سهماً من خلال خطة استثمار الأسهم المؤجلة للمديرين.

تم اعتماد RSU بناءً على توزيع الشركة البالغ $0.19 للسهم وبسعر إغلاق قدره $123.65. تم شراء 223 سهم بسعر متوسط وزني قدره $123.21. عقب هذه المعاملات، يملك المدير اقتصاديًا بشكل مباشر 6,904 أسهم.

Encompass Health (EHC)2025/10/15 报告了董事的 Form 4 活动。董事收到与普通股股息相关的 7 RSU,并通过 Directors Deferred Stock Investment Plan 取得了 223 股

RSU 的记账基于公司每股 $0.19 的股息和收盘价 $123.65。这 223 股 以加权平均价格 $123.21 购买。完成这些交易后,该董事直接实际拥有 6,904 股。

Positive
  • None.
Negative
  • None.

Encompass Health (EHC) ha riportato un'attività del modulo 4 del direttore il 15/10/2025. Il direttore ha ricevuto 7 RSU accreditate in relazione a un dividendo di azioni comuni e ha acquistato 223 azioni attraverso il Directors Deferred Stock Investment Plan.

Le RSU sono state accreditate sulla base del dividendo della società di $0.19 per azione e di una chiusura del prezzo di $123.65. Le 223 azioni sono state acquistate a un prezzo medio ponderato di $123.21. Dopo queste operazioni, il direttore detiene in modo beneficiario 6,904 azioni direttamente.

Encompass Health (EHC) informó una actividad del Formulario 4 del director el 15/10/2025. El/la director(a) recibió 7 RSU acreditadas en relación con un dividendo de acciones comunes y adquirió 223 acciones a través del Directors Deferred Stock Investment Plan.

Las RSU se acreditaron sobre la base del dividendo de la empresa de $0.19 por acción y un precio de cierre de $123.65. Las 223 acciones se compraron a un precio medio ponderado de $123.21. Después de estas transacciones, el/la director(a) posee de manera beneficiosa 6,904 acciones directamente.

Encompass Health (EHC)는 이사(감) 관할 Form 4 활동을 2025년 10월 15일에 보고했습니다. 이사는 일반 주식 배당과 관련하여 7 RSU를 수령했고 223주를 Directors Deferred Stock Investment Plan을 통해 취득했습니다.

RSU는 회사의 주당 배당금 $0.19와 마감가 $123.65를 기준으로 적립되었습니다. 223주는 가중 평균가 $123.21로 매수되었습니다. 이 거래 후 이사는 직접적으로 6,904주를 유익하게 소유합니다.

Encompass Health (EHC) a signalé une activité Form 4 du directeur le 15/10/2025. Le directeur a reçu 7 RSU créditées dans le cadre d’un dividende d’actions ordinaires et a acquis 223 actions via le Directors Deferred Stock Investment Plan.

Les RSU ont été créditées sur la base du dividende de $0.19 par action et d’un cours de clôture de $123.65. Les 223 actions ont été achetées à un prix moyen pondéré de $123.21. Suite à ces transactions, le directeur détient directement de façon bénéficiaire 6,904 actions.

Encompass Health (EHC) meldete eine Director’s Form 4-Aktivität am 10/15/2025. Der Direktor erhielt 7 RSUs, die im Zusammenhang mit einer Dividende auf Stammaktien gutgeschrieben wurden, und erwarb 223 Aktien durch den Directors Deferred Stock Investment Plan.

Die RSUs wurden basierend auf der Dividende des Unternehmens von $0.19 pro Aktie und einem Schlusskurs von $123.65 gutgeschrieben. Die 223 Aktien wurden zu einem gewichteten Durchschnittspreis von $123.21 gekauft. Nach diesen Transaktionen besitzt der Direktor direkt wirtschaftlich 6,904 Aktien.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Christie Edward M III

(Last) (First) (Middle)
9001 LIBERTY PARKWAY

(Street)
BIRMINGHAM AL 35242

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Encompass Health Corp [ EHC ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/15/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Encompass Health Common Stock 10/15/2025 A 7(1) A $0 6,681 D
Encompass Health Common Stock 10/15/2025 A 223(2) A $123.21(3) 6,904 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. Pursuant to outstanding restricted stock unit award agreements, additional restricted stock units ("RSUs") are credited to each non-employee director's account in connection with common stock dividend payments, The number of RSUs credited is equal to (a) the product of (i) the number of the RSUs in each director's account on the associated dividend record date and (ii) the per share dividend, divided by (b) the closing price on the dividend payment date. On October 15, 2025, Encompass Health paid a dividend on its common stock of $0.19 per share and the closing price was $123.65. The transaction reported on this Form 4 is an award of RSUs associated with that dividend payment.
2. The Directors Deferred Stock Investment Plan of the Company is a non-qualified deferral plan adopted and approved by the Board of Directors, effective November 1, 2007, allowing non-employee directors to make elections during 2024 to defer fixed percentages of their director fees for 2025. The amount each participant defers under the Plan is deducted, on a quarterly basis, from the directors fees the participant would otherwise have received in cash. The deferred fees fund the purchase of the Company's common stock by the Plan administrator in the market for the account of each participating director, and under the terms of the Plan, such stock is entitled to cash dividends that are reinvested by the Plan administrator in the Company's common stock. The number reported represents shares purchased with the quarterly fee deferral and the dividend of $0.19 per share paid on October 15, 2025.
3. This per share price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $123.20 to $123.21, inclusive. The reporting person undertakes to provide to Encompass Health Corporation, any of its security holders, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within this range.
/s/Patrick Darby, attorney-in-fact for Mr. Christie 10/16/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Encompass Health (EHC) disclose in this Form 4?

A director reported receiving 7 RSUs tied to a dividend and acquiring 223 shares through the Directors Deferred Stock Investment Plan on 10/15/2025.

How many Encompass Health shares does the director own after the transactions?

Following the reported transactions, the director beneficially owns 6,904 shares directly.

What price was used for the RSU dividend credit and what was the dividend?

The RSUs were credited using a closing price of $123.65 and a dividend of $0.19 per share paid on 10/15/2025.

At what price were the 223 shares acquired?

The shares were purchased at a weighted average price of $123.21, with trades ranging from $123.20 to $123.21.

What is the Directors Deferred Stock Investment Plan mentioned by EHC?

It is a non-qualified plan allowing non-employee directors to defer fees, which fund market purchases of EHC common stock and reinvest cash dividends.

Was any cash paid for the 7 RSUs?

No. The 7 RSUs were credited in connection with the common stock dividend and show a price of $0 on the form.
Encompass Health Corp

NYSE:EHC

EHC Rankings

EHC Latest News

EHC Latest SEC Filings

EHC Stock Data

12.45B
99.13M
1.41%
96.12%
1.28%
Medical Care Facilities
Services-hospitals
Link
United States
BIRMINGHAM